NeuroSense Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
NeuroSense Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-16.2%
Buyback Yield
| Total Shareholder Yield | -16.2% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely
Mar 22
Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?
Dec 06Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?
Mar 03Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?
Nov 17NeuroSense Therapeutics GAAP EPS of -$0.55
Aug 31We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate
Jul 06NeuroSense climbs 66% after early data supporting Alzheimer’s candidate
Jun 30Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?
Mar 31NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans
Mar 22NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases
Dec 22Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if NRSN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NRSN's dividend payments have been increasing.
Dividend Yield vs Market
| NeuroSense Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (NRSN) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Biotechs) | 1.7% |
| Analyst forecast (NRSN) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate NRSN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NRSN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate NRSN's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NRSN has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 10:23 |
| End of Day Share Price | 2025/02/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NeuroSense Therapeutics Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Nazibur Rahman | Maxim Group |